全文获取类型
收费全文 | 281680篇 |
免费 | 26444篇 |
国内免费 | 20557篇 |
专业分类
耳鼻咽喉 | 2266篇 |
儿科学 | 2909篇 |
妇产科学 | 3445篇 |
基础医学 | 35294篇 |
口腔科学 | 4547篇 |
临床医学 | 39637篇 |
内科学 | 42024篇 |
皮肤病学 | 2686篇 |
神经病学 | 16801篇 |
特种医学 | 10163篇 |
外国民族医学 | 198篇 |
外科学 | 27642篇 |
综合类 | 44642篇 |
现状与发展 | 75篇 |
一般理论 | 54篇 |
预防医学 | 17352篇 |
眼科学 | 8706篇 |
药学 | 29455篇 |
299篇 | |
中国医学 | 15606篇 |
肿瘤学 | 24880篇 |
出版年
2024年 | 936篇 |
2023年 | 4452篇 |
2022年 | 11557篇 |
2021年 | 14380篇 |
2020年 | 10864篇 |
2019年 | 9579篇 |
2018年 | 10090篇 |
2017年 | 8776篇 |
2016年 | 8448篇 |
2015年 | 12571篇 |
2014年 | 15454篇 |
2013年 | 13331篇 |
2012年 | 19853篇 |
2011年 | 22592篇 |
2010年 | 13680篇 |
2009年 | 10675篇 |
2008年 | 14347篇 |
2007年 | 14381篇 |
2006年 | 14512篇 |
2005年 | 14846篇 |
2004年 | 9213篇 |
2003年 | 8546篇 |
2002年 | 7230篇 |
2001年 | 6035篇 |
2000年 | 6769篇 |
1999年 | 7505篇 |
1998年 | 4949篇 |
1997年 | 4913篇 |
1996年 | 3840篇 |
1995年 | 3678篇 |
1994年 | 3015篇 |
1993年 | 2112篇 |
1992年 | 2451篇 |
1991年 | 2059篇 |
1990年 | 1796篇 |
1989年 | 1562篇 |
1988年 | 1344篇 |
1987年 | 1180篇 |
1986年 | 945篇 |
1985年 | 825篇 |
1984年 | 520篇 |
1983年 | 349篇 |
1982年 | 263篇 |
1981年 | 277篇 |
1980年 | 210篇 |
1979年 | 204篇 |
1977年 | 96篇 |
1976年 | 117篇 |
1975年 | 101篇 |
1974年 | 130篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Xiaojie Wu Leyan Zhang Jiadi Zhou Luying Liu Qiang Fu Aili Fu Xiaoying Feng Rui Xin Hongrui Liu Yong Gao Jiangnan Xue 《Current problems in cancer》2019,43(1):18-26
Aim
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor which is expressed within most types of hematopoietic cells and negatively regulates immune responses. Recently, we found LAIR-1 expression to be present within tumors of nonhematopoietic lineages. However, the roles of LAIR-1 in hepatocellular carcinoma (HCC) have yet to be examined. The purpose of this study was to investigate the expression of LAIR-1 in HCC tissue and assess its clinical significance at this site.Materials and methods
Expression levels of LAIR-1 within HCC samples collected from 90 patients and compared with that of slides of normal liver tissue collected from 9 non-HCC patients were measured by immunohistochemistry using tissue microarrays. A semiquantitative score was assigned, as was based on staining intensity and percent of positive cells and a Spearman Rank correlation test was used to assess any potential significant correlations between LAIR-1 expression and clinicopathological factors. Overall survival analysis was performed using the Kaplan-Meier and Log Rank statistical test.Results
LAIR-1 expression was detected in cancer tissue and adjacent tumor tissue, but not in normal liver tissue. The percent of LAIR-1-positive expression in cancer tissue of HCC samples was 97.78% (88/90) while that in adjacent tumor tissue was 96.67% (87/90). Significantly greater expression levels of LAIR-1 were obtained from cancer tissue (Mean?±?SD?=?5.722?±?2.145) than that in adjacent tumor tissue (4.141?±?1.486). In addition, LAIR-1 expression was found to be significantly correlated with pathological grade of HCC, T stage, and age. Expression levels of LAIR-1 were related with worse overall survival rates of HCC patients, especially in HCC patients with hepatic cirrhosis.Conclusion
Results of this study show that LAIR-1 is expressed in HCC tissues and that high levels of LAIR-1 expression are associated with the poor cancer differentiation. In addition, overexpression of LAIR-1 was significantly associated with worse overall survival in the patients with HCC. These data suggest that LAIR-1 may be an independent predictor for clinical outcomes in patients with HCC. 相似文献92.
93.
目的:总结主动脉窦瘤破裂的手术适应症、手术方法和预后。方法:回顾性分析2011年1月至2017年12月因主动脉窦瘤破裂于我院行外科手术治疗的130名患者资料。其中男性58例(44.62%),女性72例(55.38%),年龄32~75(52.72±13.87)岁。合并室间隔缺损55例(42.31%),合并主动脉瓣关闭不全39例(30%),合并房间隔缺损12例(9.23%),合并三尖瓣关闭不全8例(6.15%),合并二尖瓣关闭不全6例(4.62%),合并主动脉夹层1例(0.77%),合并其他心脏疾病9例(6.92%);破裂开口起源于右冠窦119例,起源于无冠窦11例。所有患者均在中低温体外循环下行手术治疗。结果:所有患者中,2例患者围术期死亡,余128例患者随访5个月至5年,术后心功能恢复至I-II级。结论:一旦发现主动脉窦瘤破裂,应积极予以治疗。 相似文献
94.
95.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献96.
本研究拟探讨染料木黄酮对前列腺癌细胞LNCaP和CWR22RV1的增殖、迁移和侵袭能力的影响。一、材料与方法1.材料:前列腺癌细胞株LNCaP和CWR22RV1(中国科学院上海生命科学研究院);Genistein(天津科瑞泰科技有限公司);RPMI 1640、胎牛血清(FBS)、胰蛋白酶(美国Gibco公司);E-钙黏蛋白(E-cadherin)、N-钙黏蛋白(N-cadherin)、波形蛋白(Vimentin,Abcam公司);聚氰基丙烯酸正丁酯(BCA)试剂盒、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)上样缓冲液(×5)及蛋白质印迹法(Western blot)试剂盒(上海市碧云天生物公司);2.实验方法:采用噻唑蓝(MTT)实验、划痕实验和Transwell实验检测Genistein对细胞增殖、迁移及侵袭能力的影响。采用Western blot检测E-cadherin、N-cadherin、Vimentin、CD44和Oct-4的表达水平。 相似文献
97.
目的 运用网状Meta分析方法评价针灸联合关节松动术治疗肩周炎的疗效。方法 运用计算机检索Web of Science、PubMed、Cochrane Library、EMbase、维普(VIP)、中国知网(CNKI)、万方(Wanfang)、中国生物医学文献数据库(CBM),搜寻有关针灸联合关节松动术治疗肩周炎的随机对照试验。所有研究人员均独立纳排文献、提录资料、风险评估,对符合质量标准的RCT研究采用Stata16.0和Review Manager 5.4软件进行分析。结果 共检索出6561篇文献,最终纳入37项研究,涉及10种针灸联合关节松动术方法。总样本量2890例,其中试验组1432例,对照组1458例。网状Meta分析所得结果表明:①在总有效率方面,最好的3种治疗方法为内热针联合组、温针联合组、动筋针联合组;②在降低VAS评分方面,最好的3种治疗方法为内热针联合组、动筋针联合组、针刀联合组。结论 针灸联合关节松动术治疗肩周炎疗效总体优于单独使用,且内热针联合组具有最佳的疗效。 相似文献
98.
99.
A Well-Balanced Positivity-Preserving Quasi-Lagrange Moving Mesh DG Method for the Shallow Water Equations
下载免费PDF全文
![点击此处可从《Communications In Computational Physics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A high-order, well-balanced, positivity-preserving quasi-Lagrange moving
mesh DG method is presented for the shallow water equations with non-flat bottom
topography. The well-balance property is crucial to the ability of a scheme to simulate perturbation waves over the lake-at-rest steady state such as waves on a lake or
tsunami waves in the deep ocean. The method combines a quasi-Lagrange moving
mesh DG method, a hydrostatic reconstruction technique, and a change of unknown
variables. The strategies in the use of slope limiting, positivity-preservation limiting,
and change of variables to ensure the well-balance and positivity-preserving properties are discussed. Compared to rezoning-type methods, the current method treats
mesh movement continuously in time and has the advantages that it does not need to
interpolate flow variables from the old mesh to the new one and places no constraint
for the choice of a update scheme for the bottom topography on the new mesh. A selection of one- and two-dimensional examples are presented to demonstrate the well-balance property, positivity preservation, and high-order accuracy of the method and
its ability to adapt the mesh according to features in the flow and bottom topography. 相似文献
100.